HomeCompareAIQUY vs JNJ

AIQUY vs JNJ: Dividend Comparison 2026

AIQUY yields 1.75% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AIQUY wins by $3.7K in total portfolio value
10 years
AIQUY
AIQUY
● Live price
1.75%
Share price
$41.50
Annual div
$0.73
5Y div CAGR
29.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.0K
Annual income
$3,492.07
Full AIQUY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — AIQUY vs JNJ

📍 AIQUY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAIQUYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AIQUY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AIQUY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AIQUY
Annual income on $10K today (after 15% tax)
$148.84/yr
After 10yr DRIP, annual income (after tax)
$2,968.26/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $1,017.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AIQUY + JNJ for your $10,000?

AIQUY: 50%JNJ: 50%
100% JNJ50/50100% AIQUY
Portfolio after 10yr
$32.1K
Annual income
$4,090.74/yr
Blended yield
12.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

AIQUY
Analyst Ratings
4
Buy
1
Sell
Consensus: Buy
Altman Z
4.8
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AIQUY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAIQUYJNJ
Forward yield1.75%2.13%
Annual dividend / share$0.73$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR29.1%28%
Portfolio after 10y$34.0K$30.3K
Annual income after 10y$3,492.07$4,689.40
Total dividends collected$12.1K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: AIQUY vs JNJ ($10,000, DRIP)

YearAIQUY PortfolioAIQUY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,926$226.06$10,592$272.30+$334.00AIQUY
2$11,989$298.01$11,289$357.73+$700.00AIQUY
3$13,223$394.53$12,123$472.89+$1.1KAIQUY
4$14,673$525.01$13,141$629.86+$1.5KAIQUY
5$16,403$702.94$14,408$846.81+$2.0KAIQUY
6$18,500$948.12$16,021$1,151.60+$2.5KAIQUY
7$21,085$1,290.15$18,122$1,588.22+$3.0KAIQUY
8$24,335$1,774.14$20,930$2,228.20+$3.4KAIQUY
9$28,509$2,470.53$24,792$3,191.91+$3.7KAIQUY
10$33,997$3,492.07$30,274$4,689.40+$3.7KAIQUY

AIQUY vs JNJ: Complete Analysis 2026

AIQUYStock

L'Air Liquide S.A. provides gases, technologies, and services for the industrial and health sectors in Europe, the Americas, the Asia Pacific, the Middle East, and Africa. The company's Gas & Services segment offers oxygen, nitrogen, argon, hydrogen, and carbon monoxide to the metals, chemicals, refining, and energy sectors; and gases, application equipment, and associated services to the materials and energy, automotive and manufacturing, food and pharmaceuticals, technology and research, and craftsmen and retail sectors. It also supplies medical gases, hygiene products, equipment, and services to hospitals, as well as to patients in their homes; and produces and distributes healthcare specialty ingredients for the cosmetics, pharmaceutical, and vaccine markets. In addition, this segment supplies gases, materials, and services for use in the production of semi-conductors, as well as flat screens and photovoltaic panels. Its Engineering & Construction segment designs, develops, and builds industrial gas production plants for third parties; and designs and manufactures plants in the traditional, renewable, and alternative energy sectors. The company's Global Markets & Technologies segment delivers technological solutions, such as molecules, equipment, and services to support the markets of energy transition, primarily in transport, energy, and waste valorization, as well as related to deep tech in the space exploration, aerospace, and big science. This segment also invests in biomethane production units, as well as develops stations for distributing natural bio-gas for vehicles and hydrogen to support clean mobility; operates biomethane production units for use in the maritime industry; and supplies gases for the offshore oil and gas platforms, offshore wind turbines, and cryogenic transportation by sea. L'Air Liquide S.A. was incorporated in 1902 and is headquartered in Paris, France.

Full AIQUY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this AIQUY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AIQUY vs SCHDAIQUY vs JEPIAIQUY vs OAIQUY vs KOAIQUY vs MAINAIQUY vs ABBVAIQUY vs MRKAIQUY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.